|
|
Article: Aventis announces approval of extended release Allegra-D (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg).(PIPELINE PREVIEWS)
- Article from:
- Journal of Drugs in Dermatology
- Article date:
- January 1, 2005
CopyrightCOPYRIGHT 2005 Journal of Drugs in Dermatology, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A 24-hour extended-release tablet form of fexofenadine HCl (Allegra-D 180 mg) made by Aventis Pharmaceuticals, Inc., was approved by the FDA for the relief of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years and older. This formulation was developed with aaiPharma using a patented ...